Healthcare · Biotechnology
Price
$10.51
Market Cap
$94.7M
Employees
153
Beta
0.11
Avg Volume
1,446,726
CEO
Anhco Nguyen
Business Description
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic malignancies and solid tumors. This includes ATA2271 and ATA3271 targeting mesothelin, alongside ATA2431 and ATA3219 for B-cell malignancies. Furthermore, Atara is developing ATA188 for the treatment of multiple sclerosis and the ATA368 program specifically for cancers associated with human papillomavirus (HPV). To bolster its research and development efforts, Atara Biotherapeutics has established significant collaborations and licensing agreements. These include a licensing partnership with Memorial Sloan Kettering Cancer Center, a license and R&D collaboration with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Additionally, the company holds a strategic partnership with Bayer AG focused on mesothelin-targeted CAR T-cell therapies for solid tumors.
Business History
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
4.03
Stock Price: $10.51
EPS (Diluted): 2.61
EPS (Diluted): 2.61
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
-5.89
Stock Price: $10.51
Total Equity: -$38.50M
Shares: 12,718,000
Total Equity: -$38.50M
Shares: 12,718,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
7.02
Market Cap: $94.70M
Total Debt: $43.45M
Cash: $8.48M
EBITDA: $38.63M
Total Debt: $43.45M
Cash: $8.48M
EBITDA: $38.63M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$271.2M
Market Cap: $94.70M
Total Debt: $43.45M
Cash: $8.48M
Total Debt: $43.45M
Cash: $8.48M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
82.4%
Gross Profit: $99.56M
Revenue: $120.77M
Revenue: $120.77M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
29.7%
Operating Income: $35.86M
Revenue: $120.77M
Revenue: $120.77M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
27.1%
Net Income: $32.69M
Revenue: $120.77M
Revenue: $120.77M
ROE (Profit from shareholder equity)
CALCNet Income / Total Equity
-84.9%
Net Income: $32.69M
Total Equity: -$38.50M
Total Equity: -$38.50M
ROIC (Profit from all invested capital)
CALCNOPAT / Invested Capital
-1,014.1%
Operating Income: $35.86M
Tax Rate: 0.1%
Equity: -$38.50M
Total Debt: $43.45M
Cash: $8.48M
Tax Rate: 0.1%
Equity: -$38.50M
Total Debt: $43.45M
Cash: $8.48M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.82
Current Assets: $12.21M
Current Liabilities: $14.92M
Current Liabilities: $14.92M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
-1.13
Short-Term Debt: $10.78M
Long-Term Debt: $32.67M
Total Debt: $43.45M
Total Equity: -$38.50M
Long-Term Debt: $32.67M
Total Debt: $43.45M
Total Equity: -$38.50M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$9.50
Revenue: $120.77M
Shares: 12,718,000
Shares: 12,718,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$-3.03
Total Equity: -$38.50M
Shares: 12,718,000
Shares: 12,718,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-4.01
Operating CF: -$50.94M
CapEx: $0.00
Shares: 12,718,000
CapEx: $0.00
Shares: 12,718,000
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $10.51
Stock Price: $10.51
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $32.69M
Net Income: $32.69M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares ATRA against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 22, 2026 11:49pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $20.3M | $63.6M | $8.6M | $128.9M | $120.8M |
| Cost of Revenue | $282.0M | $270.0M | $8.9M | $21.0M | $21.2M |
| Gross Profit | -$261.7M | -$206.4M | $-313,000 | $107.9M | $99.6M |
| Operating Expenses | $78.8M | $74.1M | $275.7M | $191.4M | $63.7M |
| Operating Income | -$340.5M | -$280.5M | -$276.0M | -$83.4M | $35.9M |
| Net Income | -$340.1M | -$228.3M | -$276.1M | -$85.4M | $32.7M |
| EBITDA | -$330.8M | -$222.3M | -$266.0M | -$75.7M | $38.6M |
| EPS | $-90.78 | $-55.96 | $-65.18 | $-11.41 | $2.61 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 22, 2026 11:49pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $106.1M | $92.9M | $25.8M | $25.0M | $8.5M |
| Total Current Assets | $384.6M | $295.1M | $101.9M | $64.9M | $12.2M |
| Total Assets | $468.1M | $376.4M | $165.5M | $109.1M | $20.2M |
| Current Liabilities | $105.8M | $78.9M | $142.2M | $134.6M | $14.9M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $32.7M |
| Total Liabilities | $188.5M | $249.8M | $264.7M | $206.4M | $58.7M |
| Total Equity | $279.6M | $126.6M | -$99.2M | -$97.3M | -$38.5M |
| Retained Earnings | -$1.5B | -$1.7B | -$2.0B | -$2.1B | -$2.0B |
Cash Flow (Annual)
Last updated: Jun 22, 2026 11:49pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$220.5M | -$270.4M | -$193.0M | -$68.7M | -$50.9M |
| Capital Expenditure | -$10.6M | -$4.2M | -$1.2M | $-246,000 | $0 |
| Free Cash Flow | -$231.1M | -$274.6M | -$194.2M | -$69.0M | -$50.9M |
| Acquisitions (net) | -$32.8M | $0 | $0 | $0 | $948,000 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$94.3M | -$14.4M | -$67.1M | $-811,000 | -$16.7M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 8:29pm (13h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$40.1M $36.0M – $44.8M
|
$22.1M $19.8M – $24.7M
|
$49.2M $44.1M – $55.0M
|
$76.8M $68.8M – $85.8M
|
| EBITDA |
-$26.2M -$29.3M – -$23.5M
|
-$14.4M -$16.1M – -$12.9M
|
-$32.1M -$35.9M – -$28.8M
|
-$50.2M -$56.1M – -$45.0M
|
| Net Income |
$11.5M $9.9M – $13.1M
|
-$3.3M -$10.4M – $3.8M
|
$22.9M $19.8M – $26.4M
|
$44.7M $38.7M – $51.5M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 22, 2026 11:49pm (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +212.6% | -86.5% | +1,404.0% | -6.3% |
| Gross Profit Growth | +21.1% | +99.8% | +34,582.7% | -7.8% |
| Operating Income Growth | +17.6% | +1.6% | +69.8% | +143.0% |
| Net Income Growth | +32.9% | -20.9% | +69.1% | +138.3% |
| EBITDA Growth | +32.8% | -19.7% | +71.5% | +151.0% |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for ATRA — it's generated by the pipeline (
market-narrative step).
No community reviews yet for ATRA.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30